---
title: "GFH375, an oral KRAS G12D inhibitor: Phase 1 safety and activity in advanced solid tumors"
id: "nature-3-oral-kras-g12d-inhibitor-gfh375-for-previously-treated-advanced-solid-tumors"
canonical_url: "https://medichelpline.com/clinical-feed/nature-3-oral-kras-g12d-inhibitor-gfh375-for-previously-treated-advanced-solid-tumors"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Nature Medicine"
source_url: "https://www.nature.com/articles/s41591-026-04559-4"
published_at: "2026-09-15T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# GFH375, an oral KRAS G12D inhibitor: Phase 1 safety and activity in advanced solid tumors
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-3-oral-kras-g12d-inhibitor-gfh375-for-previously-treated-advanced-solid-tumors
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Nature Medicine
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41591-026-04559-4)
- **Published At:** 2026-09-15T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The study reports a phase 1, first-in-human, dose-escalation trial of oral **GFH375**, designed to inhibit **KRAS G12D** by targeting both the GTP-bound (‘ON’) and GDP-bound (‘OFF’) states of the mutant protein. - Primary endpoints were safety/tolerability, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Secondary endpoints included pharmacokinetics, objective response rate (**ORR**), duration of response, disease control rate, time to response, progression-free survival (PFS) and overall survival (OS). - Seventy-four heavily pretreated patients with KRAS G12D–mutant advanced solid tumors received oral GFH375 once or twice daily. Tumor types included 43 pancreatic ductal adenocarcinoma (PDAC) patients, 16 non-small-cell lung cancer (NSCLC) patients and 10 colorectal cancer (CRC) patients. - In the dose-escalation cohort (22 patients) no dose-limiting toxicity (DLT) was observed and the MTD was not reached. The RP2D was set at 600 mg once daily. - Overall GFH375 was described as well tolerated. One treatment-related grade 5 adverse event (septic shock) was reported. Grade ≥3 treatment-related adverse events occurred in 36.5% (27/74) of patients and were more common in patients with prior immune checkpoint inhibitor therapy. - Antitumor activity: In PDAC, confirmed **ORR** was 35.1% (13/37) with a median duration of response of 5.6 months; median PFS and OS were 5.5 and 9.9 months, respectively. In NSCLC, confirmed ORR was 35.7% (5/14); median PFS and OS were 5.5 and 13.4 months, respectively. - The report notes ctDNA analyses with co-occurring gene alterations (figures provided) but detailed co-mutation outcomes beyond figure summaries are in the full article. - The phase 2 expansion cohorts for NSCLC, PDAC, CRC and other solid tumors are ongoing. ClinicalTrials.gov identifier: NCT06500676. - Data availability is restricted by intellectual-property and confidentiality requirements; deidentified participant data may be available on request after trial finalization, subject to a data access agreement. The molecular structure of GFH375 is referenced via a patent (WO2024061370) and supplementary material.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41591-026-04559-4#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Medicine](https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg) ](https://www.nature.com/nm) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-026-04559-4) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nm/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nm/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nm/news-and-comment) * [ Podcasts ](https://www.nature.com/nm/podcast) * [ Current issue ](https://www.nature.com/nm/current-issue) * [ Collections ](https://www.nature.com/nm/collections) * [Follow us on Facebook ](https://www.facebook.com/Nature-Medicine-193691346949/) * [Follow us on X ](https://twitter.com/naturemedicine) * [ Subscribe ](https://www.nature.com/nm/subscribe) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nm/aims) * [ Journal Information ](https://www.nature.com/nm/journal-information) * [ Journal Metrics ](https://www.nature.com/nm/journal-impact) * [ About the Editors ](https://www.nature.com/nm/editors) * [ Research Cross-Journal Editorial Team ](https://www.nature.com/nm/research-cross-journal-editorial-team) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nm/reviews-cross-journal-editorial-team) * [ Statistical Advisory Panel ](https://www.nature.com/nm/statistics-advisory-panel) * [ Our publishing models ](https://www.nature.com/nm/our-publishing-models) * [ Editorial Values Statement ](https://www.nature.com/nm/editorial-values-statement) * [ Editorial Policies ](https://www.nature.com/nm/editorial-policies) * [ Content Types ](https://www.nature.com/nm/content) * [ Web Feeds ](https://www.nature.com/nm/web-feeds) * [ Contact ](https://www.nature.com/nm/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ Submission Guidelines ](https://www.nature.com/nm/submission-guidelines) * [ For Reviewers ](https://www.nature.com/nm/for-reviewers) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/nm/open-access-funding) * [Submit manuscript ](https://mts-nmed.nature.com/cgi-bin/main.plex) * [ Subscribe ](https://www.nature.com/nm/subscribe) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) 1. [nature](https://www.nature.com/) 2. [nature medicine](https://www.nature.com/nm) 3. [articles](https://www.nature.com/nm/articles?type=article) 4. article * Article * Published: 15 September 2026 # Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with _KRAS_ G12D mutations: a phase 1 trial * [Xinghao Ai](https://www.nature.com/articles/s41591-026-04559-4#auth-Xinghao-Ai-Aff1)[1](https://www.nature.com/articles/s41591-026-04559-4#Aff1), * [Zhengbo Song](https://www.nature.com/articles/s41591-026-04559-4#auth-Zhengbo-Song-Aff2)[2](https://www.nature.com/articles/s41591-026-04559-4#Aff2), * [Lin Wu](https://www.nature.com/articles/s41591-026-04559-4#auth-Lin-Wu-Aff3) [ORCID: orcid.org/0000-0001-7078-7767](https://orcid.org/0000-0001-7078-7767)[3](https://www.nature.com/articles/s41591-026-04559-4#Aff3), * [Aiping Zhou](https://www.nature.com/articles/s41591-026-04559-4#auth-Aiping-Zhou-Aff4)[4](https://www.nature.com/articles/s41591-026-04559-4#Aff4), * [Di Cheng](https://www.nature.com/articles/s41591-026-04559-4#auth-Di-Cheng-Aff5)[5](https://www.nature.com/articles/s41591-026-04559-4#Aff5), * [Hong Zong](https://www.nature.com/articles/s41591-026-04559-4#auth-Hong-Zong-Aff6)[6](https://www.nature.com/articles/s41591-026-04559-4#Aff6), * [Heshui Wu](https://www.nature.com/articles/s41591-026-04559-4#auth-Heshui-Wu-Aff7)[7](https://www.nature.com/articles/s41591-026-04559-4#Aff7), * [Zuoxing Niu](https://www.nature.com/articles/s41591-026-04559-4#auth-Zuoxing-Niu-Aff8)[8](https://www.nature.com/articles/s41591-026-04559-4#Aff8), * [Yuping Sun](https://www.nature.com/articles/s41591-026-04559-4#auth-Yuping-Sun-Aff8)[8](https://www.nature.com/articles/s41591-026-04559-4#Aff8), * [Lingjun Zhu](https://www.nature.com/articles/s41591-026-04559-4#auth-Lingjun-Zhu-Aff9)[9](https://www.nature.com/articles/s41591-026-04559-4#Aff9), * [Zhiwei Li](https://www.nature.com/articles/s41591-026-04559-4#auth-Zhiwei-Li-Aff10)[10](https://www.nature.com/articles/s41591-026-04559-4#Aff10), * [Yanhong Deng](https://www.nature.com/articles/s41591-026-04559-4#auth-Yanhong-Deng-Aff11)[11](https://www.nature.com/articles/s41591-026-04559-4#Aff11), * [Ying Yuan](https://www.nature.com/articles/s41591-026-04559-4#auth-Ying-Yuan-Aff12) [ORCID: orcid.org/0000-0002-3922-9553](https://orcid.org/0000-0002-3922-9553)[12](https://www.nature.com/articles/s41591-026-04559-4#Aff12), * [Xiujuan Qu](https://www.nature.com/articles/s41591-026-04559-4#auth-Xiujuan-Qu-Aff13)[13](https://www.nature.com/articles/s41591-026-04559-4#Aff13), * [Haitao Zhao](https://www.nature.com/articles/s41591-026-04559-4#auth-Haitao-Zhao-Aff14) [ORCID: orcid.org/0000-0002-3444-8044](https://orcid.org/0000-0002-3444-8044)[14](https://www.nature.com/articles/s41591-026-04559-4#Aff14), * [Yingying Du](https://www.nature.com/articles/s41591-026-04559-4#auth-Yingying-Du-Aff15)[15](https://www.nature.com/articles/s41591-026-04559-4#Aff15), * [Ziming Li](https://www.nature.com/articles/s41591-026-04559-4#auth-Ziming-Li-Aff1)[1](https://www.nature.com/articles/s41591-026-04559-4#Aff1), * [Yu Wang](https://www.nature.com/articles/s41591-026-04559-4#auth-Yu-Wang-Aff16)[16](https://www.nature.com/articles/s41591-026-04559-4#Aff16), * [Haige Shen](https://www.nature.com/articles/s41591-026-04559-4#auth-Haige-Shen-Aff16)[16](https://www.nature.com/articles/s41591-026-04559-4#Aff16), * [Huaqiang Zhu](https://www.nature.com/articles/s41591-026-04559-4#auth-Huaqiang-Zhu-Aff16)[16](https://www.nature.com/articles/s41591-026-04559-4#Aff16), * [Chanli Zheng](https://www.nature.com/articles/s41591-026-04559-4#auth-Chanli-Zheng-Aff16)[16](https://www.nature.com/articles/s41591-026-04559-4#Aff16), * [Shuang Wang](https://www.nature.com/articles/s41591-026-04559-4#auth-Shuang-Wang-Aff16)[16](https://www.nature.com/articles/s41591-026-04559-4#Aff16), * [Zhao Cui](https://www.nature.com/articles/s41591-026-04559-4#auth-Zhao-Cui-Aff16)[16](https://www.nature.com/articles/s41591-026-04559-4#Aff16), * [Lingyu Tai](https://www.nature.com/articles/s41591-026-04559-4#auth-Lingyu-Tai-Aff16)[16](https://www.nature.com/articles/s41591-026-04559-4#Aff16) & * … * [Shun Lu](https://www.nature.com/articles/s41591-026-04559-4#auth-Shun-Lu-Aff1) [ORCID: orcid.org/0000-0001-8833-7262](https://orcid.org/0000-0001-8833-7262)[1](https://www.nature.com/articles/s41591-026-04559-4#Aff1) Show authors [_Nature Medicine_](https://www.nature.com/nm) **volume 32**, pages 3302–3312 (2026) [Cite this article](https://www.nature.com/articles/s41591-026-04559-4#citeas) [ Save article ](https://www.nature.com/articles/s41591-026-04559-4/save-research?_csrf=31cCBBHEZ_8DpvMwy1655R896v0GHVWG) [ View saved research ](https://www.nature.com/saved-research) ## Abstract Kirsten rat sarcoma viral oncogene homolog (_KRAS_)G12D is the most prevalent _RAS_ mutation in solid tumors, associated with poor prognosis, and occurs mainly in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). Here we evaluated GFH375, a compound that targets both ‘ON’ (GTP-bound) and ‘OFF’ (GDP-bound) states of KRASG12D proteins, in a phase 1 dose-escalation trial in patients with advanced solid tumors harboring the _KRAS_ G12D mutation. The primary endpoints were safety/tolerability, the maximum tolerated dose and recommended phase 2 dose. The secondary endpoints included pharmacokinetics, objective response rate (ORR), duration of response, disease control rate, time to response, progression-free survival (PFS) and overall survival (OS). A total of 74 heavily treated patients with _KRAS_ G12D-mutant advanced solid tumors were administered orally with GFH375 once or twice daily, including 43 patients with PDAC, 16 with NSCLC and 10 with CRC. Overall, GFH375 was well tolerated and no dose-limiting toxicity was observed among the 22 patients in the dose-escalation part; the maximum tolerated dose was not reached. The recommended phase 2 dose of GFH375 was declared as 600 mg once daily. One (1.4%) grade 5 treatment-related adverse event was reported as septic shock. Grade ≥3 treatment-related adverse events occurred in 36.5% (27/74) of the patients and were more prevalent in patients previously treated with immune checkpoint inhibitors. In patients with PDAC, the confirmed ORR was 35.1% (13/37), with a median duration of response of 5.6 months; the median PFS and median OS were 5.5 months and 9.9 months, respectively. In patients with NSCLC, the confirmed ORR was 35.7% (5/14); the median PFS and median OS were 5.5 months and 13.4 months, respectively. This trial demonstrated the manageable safety/tolerability and encouraging antitumor activity of GFH375 monotherapy. The phase 2 portion of this trial with expansion cohorts for NSCLC, PDAC, CRC and other solid tumors is ongoing. ClinicalTrials.gov identifier: [NCT06500676](https://clinicaltrials.gov/study/NCT06500676). This is a preview of subscription content, [access via your institution](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-026-04559-4) ## Access options [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-026-04559-4) Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 € / 30 days cancel any time [Learn more](https://shop.nature.com/products/plus/?region=ROW) Subscribe to this journal Receive 12 print issues and online access 251,40 € per year only 20,95 € per issue [Learn more](https://www.nature.com/nm/subscribe) Buy this article * Purchase on SpringerLink * Instant access to the full article PDF. 39,95 € Prices may be subject to local taxes which are calculated during checkout ### Additional access options: * [Log in](https://idp.nature.com/authorize/natureuser?client_id=grover&redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-026-04559-4) * [Learn about institutional subscriptions](https://www.springernature.com/gp/librarians/licensing/license-options) * [Read our FAQs](https://support.nature.com/en/support/home) * [Contact customer support](https://www.springernature.com/gp/contact) **Fig. 1: Patient disposition.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41591-026-04559-4/MediaObjects/41591_2026_4559_Fig1_HTML.png) **Fig. 2: Antitumor activity of GFH375 in patients with PDAC, NSCLC and other solid tumors.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41591-026-04559-4/MediaObjects/41591_2026_4559_Fig2_HTML.png) **Fig. 3: Co-occurring gene alterations detected in ctDNA at baseline and patient clinical response.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41591-026-04559-4/MediaObjects/41591_2026_4559_Fig3_HTML.png) ### Explore related subjects Discover the latest articles and news in related subjects. * [Non-small-cell lung cancer](https://www.nature.com/subjects/non-small-cell-lung-cancer) * [Pancreatic cancer](https://www.nature.com/subjects/pancreatic-cancer) * [Targeted therapies](https://www.nature.com/subjects/targeted-therapies) ## Data availability Owing to intellectual property, confidentiality obligations and regulations, individual deidentified participant data that underlie the results reported in this article may be available after completion of the first-in-human trial with the clinical study report finalization. The request can be sent to the corresponding author, and the leading clinical site and sponsor will review the request to ensure compliance with intellectual property, confidentiality obligations and regulations and will respond within 2 weeks. Data are only available upon request to protect the privacy of the company and clinical trial participants. A signed data access agreement with the sponsor is required before any data can be shared. The trial protocol and statistical analysis plan are available alongside the published article. The molecular structure of GFH375 has been published (referring to the patent number WO2024061370; Supplementary Fig. [1](https://www.nature.com/articles/s41591-026-04559-4#MOESM1)). ## References 1. Lee, J. K. et al. Comprehensive pan-cancer genomic landscape of _KRAS_ altered cancers and real-world outcomes in solid tumors. _npj Precis. Oncol._ **6** , 91 (2022). [Article](https://doi.org/10.1038%2Fs41698-022-00334-z) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XjtFSmtbrN) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36494601) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734185) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Comprehensive%20pan-cancer%20genomic%20landscape%20of%20KRAS%20altered%20cancers%20and%20real-world%20outcomes%20in%20solid%20tumors&journal=npj%20Precis.%20Oncol.&doi=10.1038%2Fs41698-022-00334-z&volume=6&publication_year=2022&author=Lee%2CJK) 2. Salem, M. E. et al. Landscape of _KRAS_ G12C, associated genomic alterations, and interrelation with immuno-oncology biomarkers in _KRAS_ -mutated cancers. _JCO Precis. Oncol._ **6** , e2100245 (2022). [Article](https://doi.org/10.1200%2FPO.21.00245) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=35319967) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966967) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Landscape%20of%20KRASG12C%2C%20associated%20genomic%20alterations%2C%20and%20interrelation%20with%20immuno-oncology%20biomarkers%20in%20KRAS-mutated%20cancers&journal=JCO%20Precis.%20Oncol.&doi=10.1200%2FPO.21.00245&volume=6&publication_year=2022&author=Salem%2CME) 3. Wu, L. et al. Pan-cancer analysis to character the clinicopathological and genomic features of KRAS-mutated patients in China. _J. Cancer Res. Clin. Oncol._ **151** , 94 (2025). [Article](https://link.springer.com/doi/10.1007/s00432-025-06118-9) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB2MXltFCrt7c%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=40016583) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11868181) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Pan-cancer%20analysis%20to%20character%20the%20clinicopathological%20and%20genomic%20features%20of%20KRAS-mutated%20patients%20in%20China&journal=J.%20Cancer%20Res.%20Clin.%20Oncol.&doi=10.1007%2Fs00432-025-06118-9&volume=151&publication_year=2025&author=Wu%2CL) 4. Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. _Nat. Med._ **23** , 703–713 (2017). [Article](https://doi.org/10.1038%2Fnm.4333) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXntFKitLo%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28481359) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461196) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Mutational%20landscape%20of%20metastatic%20cancer%20revealed%20from%20prospective%20clinical%20sequencing%20of%2010%2C000%20patients&journal=Nat.%20Med.&doi=10.1038%2Fnm.4333&volume=23&pages=703-713&publication_year=2017&author=Zehir%2CA) 5. Buscail, L., Bournet, B. & Cordelier, P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. _Nat. Rev. Gastroenterol. Hepatol._ **17** , 153–168 (2020). [Article](https://doi.org/10.1038%2Fs41575-019-0245-4) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXjvFyjtbg%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32005945) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Role%20of%20oncogenic%20KRAS%20in%20the%20diagnosis%2C%20prognosis%20and%20treatment%20of%20pancreatic%20cancer&journal=Nat.%20Rev.%20Gastroenterol.%20Hepatol.&doi=10.1038%2Fs41575-019-0245-4&volume=17&pages=153-168&publication_year=2020&author=Buscail%2CL&author=Bournet%2CB&author=Cordelier%2CP) 6. Yousef, A. et al. Impact of _KRAS_ mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. _npj Precis. Oncol._ **8** , 27 (2024). [Article](https://doi.org/10.1038%2Fs41698-024-00505-0) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB2cXjtVWntLs%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38310130) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10838312) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Impact%20of%20KRAS%20mutations%20and%20co-mutations%20on%20clinical%20outcomes%20in%20pancreatic%20ductal%20adenocarcinoma&journal=npj%20Precis.%20Oncol.&doi=10.1038%2Fs41698-024-00505-0&volume=8&publication_year=2024&author=Yousef%2CA) 7. Osterlund, E. et al. _KRAS_ and _NRAS_ mutations in Nordic population-based and real-world metastatic colorectal c
## Related Clinical Research

- [Cancer type–specific chromatin regulator mutations linked to better survival after immune checkpoi](https://medichelpline.com/clinical-feed/medrxiv-17-cancer-type-specific-profiling-of-chromatin-regulator-mutations-identifies.md)
- [Healthy lifestyle and pan-cancer risk: UK Biobank prospective analysis](https://medichelpline.com/clinical-feed/british-journal-of-cancer-2-healthy-lifestyle-and-cancer-risk-a-pan-cancer-analysis-in-the-uk-biobank.md)
- [Residential proximity to nuclear power plants and cancer incidence in South Korea: Inverse-distanc](https://medichelpline.com/clinical-feed/pubmed-42480832.md) (DOI: 10.1016/j.envres.2026.125296)
- [Sotagliflozin Modulates DNMT1 and HDAC Expression Alongside Anticancer Effects in Breast and Lung](https://medichelpline.com/clinical-feed/pubmed-42677956.md) (DOI: 10.1002/cbin.70201)
- [Late-stage cancer incidence as a screening-trial endpoint: an LLM-assisted evidence audit](https://medichelpline.com/clinical-feed/medrxiv-6-llm-assisted-evidence-audit-of-late-stage-cancer-incidence-as-a-screening-trial.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.